- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Advances in Hematology
Volume 2012 (2012), Article ID 727683, 12 pages
Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
1Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
2Rush University Cancer Center, 1725 West Harrison Street, Chicago, IL 60612, USA
3Section of Hematology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
4Department of Anatomy and Cell Biology, Rush University Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
Received 18 June 2012; Accepted 4 August 2012
Academic Editor: Seiji Fukuda
Copyright © 2012 Sucheta Jagan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. Kern and E. H. Estey, “High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials,” Cancer, vol. 107, no. 1, pp. 116–124, 2006.
- H. Kantarjian, G. Garcia-Manero, S. O'Brien et al., “Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 285–291, 2010.
- M. S. Tallman, D. G. Gilliland, and J. M. Rowe, “Drug therapy for acute myeloid leukemia,” Blood, vol. 106, no. 4, pp. 1154–1163, 2005.
- K. F. Bradstock, J. P. Matthews, R. M. Lowenthal et al., “A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine,” Blood, vol. 105, no. 2, pp. 481–488, 2005.
- F. Ravandi, H. Kantarjian, F. Giles, and J. Cortes, “New agents in acute myeloid leukemia and other myeloid disorders,” Cancer, vol. 100, no. 3, pp. 441–454, 2004.
- E. Estey and H. Dohner, “Acute myeloid leukaemia,” The Lancet, vol. 368, no. 9550, pp. 1894–1907, 2006.
- S. Grant, “Ara-C: cellular and molecular pharmacology,” Advances in Cancer Research, vol. 72, pp. 197–233, 1997.
- C. M. Galmarini, J. R. Mackey, and C. Dumontet, “Nucleoside analogues: mechanisms of drug resistance and reversal strategies,” Leukemia, vol. 15, no. 6, pp. 875–890, 2001.
- C. M. Galmarini, X. Thomas, F. Calvo et al., “Potential mechanisms of resistance to cytarabine in AML patients,” Leukemia Research, vol. 26, no. 7, pp. 621–629, 2002.
- E. J. Fox, “Mechanism of action of mitoxantrone,” Neurology, vol. 63, no. 12, supplement 6, pp. S15–S18, 2004.
- K. Bhalla, A. M. Ibrado, E. Tourkina et al., “High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells,” Blood, vol. 82, no. 10, pp. 3133–3140, 1993.
- K. M. Rentsch, D. H. Horber, R. A. Schwendener, H. Wunderli-Allenspach, and E. Hänseler, “Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice,” British Journal of Cancer, vol. 75, no. 7, pp. 986–992, 1997.
- A. Azuma, P. Huang, A. Matsuda, and W. Plunkett, “2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G2 arrest,” Molecular Pharmacology, vol. 59, no. 4, pp. 725–731, 2001.
- A. Azuma, P. Huang, A. Matsuda, and W. Plunkett, “Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC),” Biochemical Pharmacology, vol. 61, no. 12, pp. 1497–1507, 2001.
- M. Serova, C. M. Galmarini, A. Ghoul et al., “Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells,” British Journal of Cancer, vol. 97, no. 5, pp. 628–636, 2007.
- K. Hanaoka, M. Suzuki, T. Kobayashi et al., “Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682),” International Journal of Cancer, vol. 82, no. 2, pp. 226–236, 1999.
- Y. Wang, X. Liu, A. Matsuda, and W. Plunkett, “Repair of 2′-C-cyano-2′-deoxy-1-β-D-arabino- pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair,” Cancer Research, vol. 68, no. 10, pp. 3881–3889, 2008.
- Y. Ge, T. L. Jensen, M. L. Stout et al., “The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines,” Cancer Research, vol. 64, no. 2, pp. 728–735, 2004.
- H. Gourdeau, L. Bibeau, F. Ouellet, D. Custeau, L. Bernier, and T. Bowlin, “Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 3, pp. 236–240, 2001.
- X. B. Kong, W. P. Tong, and T. C. Chou, “Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine,” Molecular Pharmacology, vol. 39, no. 2, pp. 250–257, 1991.
- T. Qin, E. M. Youssef, J. Jelinek et al., “Effect of cytarabine and decitabine in combination in human leukemic cell lines,” Clinical Cancer Research, vol. 13, no. 14, pp. 4225–4232, 2007.
- W. Fiskus, R. Rao, P. Fernandez et al., “Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor resistant acute myeloid leukemia cells,” Blood, vol. 112, no. 7, pp. 2896–2905, 2008.
- C. M. Li, X. G. Liu, X. C. Lin, X. W. Chen, and N. C. Liang, “Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme,” Chinese Journal of Cancer, vol. 27, no. 8, pp. 809–815, 2008.
- W. S. Dalton, L. Hazlehurst, K. Shain, T. Landowski, and M. Alsina, “Targeting the bone marrow microenvironment in hematologic malignancies,” Seminars in Hematology, vol. 41, supplement 2, part 4, pp. 1–5, 2004.
- Z.-W. Li and W. S. Dalton, “Tumor microenvironment and drug resistance in hematologic malignancies,” Blood Reviews, vol. 20, no. 6, pp. 333–342, 2006.
- M. B. Meads, L. A. Hazlehurst, and W. S. Dalton, “The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance,” Clinical Cancer Research, vol. 14, no. 9, pp. 2519–2526, 2008.
- S. M. Garrido, F. R. Appelbaum, C. L. Willman, and D. E. Banker, “Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5),” Experimental Hematology, vol. 29, no. 4, pp. 448–457, 2001.
- B. Moshaver, M. van der Pol, A. Westra, G. Ossenkoppele, S. Zweegman, and G. J. Schuurhuis, “Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival,” Leukemia and Lymphoma, vol. 49, no. 1, pp. 134–148, 2008.
- D. G. Bouzianas, “Cobblestone area measuring (CAM) assay: a new way of assessing the potential of human haemopoietic stem cells,” Methods in Cell Science, vol. 25, no. 3-4, pp. 201–210, 2003.
- J. Edelmann, L. Klein-Hitpass, A. Carpinteiro et al., “Bone marrow fibroblasts induce expression of PI3K/NF-κB pathway genes and a pro-angiogenic phenotype in CLL cells,” Leukemia Research, vol. 32, no. 10, pp. 1565–1572, 2008.
- B. Nervi, P. Ramirez, M. P. Rettig et al., “Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100,” Blood, vol. 113, no. 24, pp. 6206–6214, 2009.
- A. Matsuda, Y. Nakajima, A. Azuma, M. Tanaka, and T. Sasaki, “Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-β-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside,” Journal of Medicinal Chemistry, vol. 34, no. 9, pp. 2917–2919, 1991.
- M. Tanaka, A. Matsuda, T. Terao, and T. Sasaki, “Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors,” Cancer Letters, vol. 64, no. 1, pp. 67–74, 1992.
- J. Gilbert, M. A. Carducci, S. D. Baker, E. C. Dees, and R. Donehower, “A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies,” Investigational New Drugs, vol. 24, no. 6, pp. 499–508, 2006.
- G. Edan, S. Morrissey, and E. Le Page, “Rationale for the use of mitoxantrone in multiple sclerosis,” Journal of the Neurological Sciences, vol. 223, no. 1, pp. 35–39, 2004.